Cassandra E. Callmann

Dr. Cassandra E. Callmann

Department of Chemistry, The University of Texas at Austin, Austin, TX 78712, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Cassandra E. CallmannCassandra E. Callmann
Cassandra E. Callmann
LCLisa E. Cole
Lisa E. Cole
CKCaroline D. Kusmierz
Caroline D. Kusmierz
ZHZiyin Huang
Ziyin Huang
DHDai Horiuchi
Dai Horiuchi
CMChad Mirkin
Chad Mirkin
Significance: In mouse models of triple-negative breast cancer, we show that the oxidation of tumor cells prior to lysate generation, coupled with their compartmentalization in the core of liposomal spherical nucleic acids (SNAs) comprised of adjuvant DNA, yields a powerful immunotherapeutic that significantly inhibits tumor growth, dramatically extends survival, and promotes a tumoricidal immune cell population within the tumor microenvironment. Specifically, this work points toward the importance of properly packaging and presenting the adjuvant and antigens such that biodistribution, dendritic cell activation, and therapeutic efficacy can be controlled.

22 January 2020 in Accounts of Chemical Research
Verified
Journal Article
Closed access
Cassandra E. CallmannCassandra E. Callmann
Cassandra E. Callmann
MTMatthew P. Thompson
Matthew P. Thompson
NGNathan C. Gianneschi
Nathan C. Gianneschi

15 April 2021 in ACS Central Science
Verified
Journal Article
Open access
Cassandra E. CallmannCassandra E. Callmann
Cassandra E. Callmann
CKCaroline D. Kusmierz
Caroline D. Kusmierz
JDJasper W. Dittmar
Jasper W. Dittmar
LBLeah Broger
Leah Broger
CMChad Mirkin
Chad Mirkin
Liposomal spherical nucleic acids (L-SNAs) show significant promise as cancer immunotherapeutics. L-SNAs are highly modular nanoscale assemblies defined by a dense, upright radial arrangement of oligonucleotides around a liposomal core. Herein, we establish a set of L-SNA design rules by studying the biological and immunological properties of L-SNAs as a function of liposome composition. To achieve this, we synthesized liposomes where the lipid phosphatidylcholine headgroup was held constant, while the diacyl lipid tail chain length and degree of saturation were varied, using either 1,2-dioleylphosphatidylcholine (DOPC), 1,2-dimyristoyl-phosphatidylcholine (DMPC), 1,2-dipalmitoylphosphatidylcholine (DPPC), or 1,2-distearoyl-phosphatidylcholine (DSPC). These studies show that the identity of the constituent lipid dictates the DNA loading, cellular uptake, serum stability, in vitro immunostimulatory activity, and in vivo lymph node accumulation of the L-SNA. Furthermore, in the 4T1 mouse model of triple-negative breast cancer (TNBC), the subcutaneous administration of immunostimulatory L-SNAs synthesized with DPPC significantly decreases the production of lung metastases and delays tumor growth as compared to L-SNAs synthesized using DOPC, due to the enhanced stability of L-SNAs synthesized with DPPC over those synthesized with DOPC. Moreover, the inclusion of cell lysates derived from Py8119 TNBC cells as antigen sources in L-SNAs leads to a significant increase in antitumor efficacy in the Py8119 model when lysates are encapsulated in the cores of L-SNAs synthesized with DPPC rather than DOPC, presumably due to increased codelivery of adjuvant and antigen to dendritic cells in vivo. This difference is further amplified when using lysates from oxidized Py8119 cells as a more potent antigen source, revealing synergy between the lysate preparation method and liposome composition in synthesizing immunotherapeutic L-SNAs. Together, this work shows that the biological properties and immunomodulatory activity of L-SNAs can be modulated by exchanging liposome components, providing another handle for the rational design of nanoscale immunotherapeutics.

27 April 2020 in ACS Central Science
Verified
Journal Article
Closed access
CKCaroline D. Kusmierz
Caroline D. Kusmierz
KBKatherine E. Bujold
Katherine E. Bujold
Cassandra E. CallmannCassandra E. Callmann
Cassandra E. Callmann
CMChad Mirkin
Chad Mirkin

10 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCSi-Cong Chen
Si-Cong Chen
XQXianjin Qin
Xianjin Qin
NXNanyu Xiong
Nanyu Xiong
LLLisha Lin
Lisha Lin
YWYanfen Wu
Yanfen Wu
XYXinshan Ye
Xinshan Ye
Fucoidan, a sulfated glycan derived from brown algae, has garnered significant attention for its anticoagulant properties. However, the structural complexity and heterogeneity of naturally extracted fucoidan have hindered a comprehensive understanding of its structure-activity relationship, limiting the development of fucoidan-based anticoagulant drugs. To address this challenge, we synthesize a diverse library of 58 distinct fucoidans with multiple contiguous 1,2-cis glycosidic bonds, ranging from disaccharides to dodecasaccharides, using a highly efficient preactivation-based one-pot glycosylation strategy. This library includes compounds with various sulfation patterns (2,3-O-di-, 3,4-O-di-, and 2,3,4-O-tri-sulfation) encompassing nearly all possible fucoidan structures. In vitro anticoagulant assays demonstrate that both molecular size and degree of sulfation play crucial roles in anticoagulant potency. Notably, compounds 29, 30, 37, and 58 significantly prolong human plasma activated partial thromboplastin time (APTT), comparable to the effect of enoxaparin, without affecting prothrombin time (PT) or thrombin time (TT). This selective inhibition of the intrinsic coagulation pathway suggests a reduced risk of bleeding, highlighting the therapeutic potential of these fucoidans as safer anticoagulant agents.

19 July 2021 in ACS Nano
Verified
Journal Article
Closed access
ZHZiyin N. Huang
Ziyin N. Huang
Cassandra E. CallmannCassandra E. Callmann
Cassandra E. Callmann
LCLisa E. Cole
Lisa E. Cole
SWShuya Wang
Shuya Wang
CMChad Mirkin
Chad Mirkin